Company news

PMV Pharmaceuticals, Inc. news in 2026

PMV Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026

November 4, 2026

PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors

October 5, 2026

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

September 8, 2026

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

August 31, 2026

PMV Pharma Announces Proposed Public Offering of Securities

August 31, 2026

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

August 31, 2026

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

August 14, 2026

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

May 12, 2026

PMV Pharmaceuticals Announces Board Chair Transition

April 22, 2026

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

March 5, 2026

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

February 26, 2026

Decks in 2026